Safe and Effective Subcutaneous Self-Injection of Bimekizumab with Safety Syringe and Auto-Injector Devices: Results from a Multicenter, Randomized, Open-Label Study in Patients with Psoriatic Arthritis

Safe and Effective Subcutaneous Self-Injection of Bimekizumab with Safety Syringe and Auto-Injector Devices: Results from a Multicenter, Randomized, Open-Label Study in Patients with Psoriatic Arthritis

Alan Kivitz,1 Alicia M Ellis,2 Vishvesh Shende,3 Jérémy Lambert,4 Daljit Tatla2 1Altoona Center for Clinical Research, Duncansville, PA, USA; 2UCB Pharma, Raleigh, NC, USA; 3UCB Pharma, Slough, UK; 4UCB Pharma, Colombes, FranceCorrespondence: Daljit Tatla, UCB Pharma, 4000 Paramount Parkway, Morrisv...

Full description

Bibliographic Details
Main Authors: Kivitz A, Ellis AM, Shende V, Lambert J, Tatla D
Format: Article
Language:English
Published: Dove Medical Press 2023-10-01
Series:Patient Preference and Adherence
Subjects:
bimekizumab
clinical trial
patient experience
psoriatic arthritis
self-injection devices
Online Access:https://www.dovepress.com/safe-and-effective-subcutaneous-self-injection-of-bimekizumab-with-saf-peer-reviewed-fulltext-article-PPA

Internet

https://www.dovepress.com/safe-and-effective-subcutaneous-self-injection-of-bimekizumab-with-saf-peer-reviewed-fulltext-article-PPA

Similar Items